These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26839978)

  • 1. Re: Prostate-specific antigen-based prostate cancer screening: Past and future.
    Birkeland S
    Int J Urol; 2016 Apr; 23(4):348. PubMed ID: 26839978
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
    Sakamoto S
    Int J Urol; 2015 Jun; 22(6):532-3. PubMed ID: 25854711
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate-specific antigen-based prostate cancer screening: Past and future.
    Alberts AR; Schoots IG; Roobol MJ
    Int J Urol; 2015 Jun; 22(6):524-32. PubMed ID: 25847604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 5. The Roles of Providers and Patients in the Overuse of Prostate-Specific Antigen Screening in the United States.
    Guo F; He D
    Ann Intern Med; 2015 Oct; 163(8):650-1. PubMed ID: 26502132
    [No Abstract]   [Full Text] [Related]  

  • 6. Is Prostate-Specific Antigen Screening "Proven Ineffective Care"?
    Barry MJ; Albertsen PC
    Ann Intern Med; 2016 May; 164(10):687-8. PubMed ID: 26902323
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific antigen testing in france.
    Braillon A
    JAMA Intern Med; 2013 Nov; 173(21):2014. PubMed ID: 24276059
    [No Abstract]   [Full Text] [Related]  

  • 8. PSA screening: the USPSTF got it right.
    Lefevre M
    J Fam Pract; 2013 Nov; 62(11):617, 619. PubMed ID: 24288702
    [No Abstract]   [Full Text] [Related]  

  • 9. Doing it right: how, not whether, to perform prostate-specific antigen screening.
    Martin NE
    Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
    [No Abstract]   [Full Text] [Related]  

  • 10. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
    Roobol MJ
    Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
    [No Abstract]   [Full Text] [Related]  

  • 11. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 12. Why I will continue to screen prostate-specific antigen for myself and other appropriate men.
    Keller DL
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394929
    [No Abstract]   [Full Text] [Related]  

  • 13. States renewing attention to prostate cancer.
    Rossiter C
    NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022
    [No Abstract]   [Full Text] [Related]  

  • 14. Why I will continue to screen prostate-specific antigen for myself and other appropriate men--reply.
    Katz MH
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394931
    [No Abstract]   [Full Text] [Related]  

  • 15. Can we stop ordering prostate-specific antigen screening tests?
    Katz MH
    JAMA Intern Med; 2013 May; 173(10):847-8. PubMed ID: 23588841
    [No Abstract]   [Full Text] [Related]  

  • 16. [PROBASE study - optimizing PSA screening].
    Setton J
    Aktuelle Urol; 2013 Nov; 44(6):431. PubMed ID: 24281932
    [No Abstract]   [Full Text] [Related]  

  • 17. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
    Gandaglia G; Briganti A; Fossati N; Salonia A; Mottrie A; Catto J; Montorsi F
    Eur Urol; 2016 Oct; 70(4):547-548. PubMed ID: 26916048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
    Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ
    BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.